Crown Bioscience announced the extension of its partnership with NEXT Oncology. This partnership will continue to leverage Crown Bioscience's experience in developing clinically relevant cancer organoid and patient-derived xenograft (PDX) models, together with NEXT Oncology's global clinical network and Phase I clinical trials expertise.
Through this extended agreement, Crown Bioscience reaffirms its exclusive rights to provide services based on patient samples sourced from NEXT Oncology’s industry-leading global clinical trial network. This collaboration underscores Crown Bioscience's commitment to providing the most clinically relevant PDX and organoid models and solutions for translational oncology research.
"We are thrilled to continue our exclusive partnership with NEXT Oncology," said John Gu, CEO of Crown Bioscience. "NEXT Oncology is globally recognized for its pioneering work in Phase I clinical oncology trials. Extending this partnership allows us to broaden our portfolio and strengthen our position as a leader in translational oncology platforms and integrated solutions. Our combined expertise and global reach will ensure rapid and scalable access to groundbreaking cancer models for our biopharma partners."
“NEXT Oncology is excited to continue our strong partnership with Crown Bioscience,” said Dr. Anthony Tolcher, CEO of NEXT Oncology. “Together, we will continue to develop new and highly relevant patient models that Crown’s biopharma partners can utilize to advance their translational oncology programs. Our combined efforts continue to support both companies’ missions to help cancer patients receive the most advanced medicines possible.”